<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60484">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02026635</url>
  </required_header>
  <id_info>
    <org_study_id>13P.296</org_study_id>
    <nct_id>NCT02026635</nct_id>
  </id_info>
  <brief_title>Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in HF Patients (CONFIRM-HF)</brief_title>
  <acronym>CONFIRM-HF</acronym>
  <official_title>Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in Heart Failure Patients (CONFIRM-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study to determine if heart failure can be medically managed using data collected
      from cardiac monitoring devices
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Physician Use of Cardiac Compass Reports to Determine HF Treatment Decisions</measure>
    <time_frame>90 days from enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment will be completed at time of enrollment and days 3 to 7, 14 to 21, 30 and 90 post discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Clinical Events</measure>
    <time_frame>90 days from enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Track HF re-admissions and other clinical encounters between 30 and 90 days post discharge for HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Patient-Reported Quality of Life</measure>
    <time_frame>90 days from enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the association between the use of Cardiac Compass Report and OptiVol®  and improved HF patient quality of life at both time points (30 and 90 days post discharge) utilizing the Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Optivol® Device in CareLink</arm_group_label>
    <description>A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        hospital inpatients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Admission for worsening of HF

          -  Discharged to home

          -  Have appropriate cardiac device with OptiVol® implanted for at least 34 days prior to
             enrollment

          -  Enrolled in Carelink® system and able to transmit data

          -  Able to participate for at least 3 months

        Exclusion Criteria:

          -  Post heart transplant or actively listed

          -  End-stage (Stage D) HF, including treatment with chronic ionotropic drugs or left
             ventricular assist device support

          -  Stage IV or V chronic renal dysfunction (GFR &lt;25 mol/min per 1.73 M2)

          -  Severe Chronic Obstructive Pulmonary Disease (COPD) requiring home oxygen

          -  Severe pulmonary hypertension not due to left-sided HF
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Whellan, MD MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David J Whellan, MD MHS</last_name>
    <phone>215 955 2007</phone>
    <email>david.whellan@jefferson.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Vinci, RN MBA</last_name>
    <phone>215 503 4883</phone>
    <email>laura.vinci@jefferson.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Vinci, RN MBA</last_name>
      <phone>215-503-4883</phone>
      <email>laura.vinci@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Mather, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphael Bonita, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon Rubin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gordon Reeves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 31, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>Optivol® cardiac device</keyword>
  <keyword>Medtronic CareLink</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
